NCT01456143 · ADVERSE EVENTS

Adverse events

Optical Imaging of Head and Neck Cancer · Source last updated 2018-02-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: (day of enrollment or up to 2 weeks after enrollment)]
Other-event reporting threshold: 0%

Serious and other adverse events were monitored and assessed, but none were observed

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
HRME With Proflavine Hemisulfate High Resolution Microendoscopy imaging device used in conjunction with proflavine hemisulfate as a contrast agent	0 / 33	0 / 33	Not reported / Not reported

Group identifiers: EG000: HRME With Proflavine Hemisulfate

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

description

Serious and other adverse events were monitored and assessed, but none were observed

event Groups

description
High Resolution Microendoscopy imaging device used in conjunction with proflavine hemisulfate as a contrast agent
id
EG000
other Num Affected
0
other Num At Risk
33
serious Num Affected
0
serious Num At Risk
33
title
HRME With Proflavine Hemisulfate

frequency Threshold

time Frame

(day of enrollment or up to 2 weeks after enrollment)]

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice